Physician profile
Daniel L Long
NPI 1033523329
$899,441.32
in general payments reported to CMS, 2019-2025
43 companies · $283K in 2025
The $283K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,845 · 2020: $36K · 2021: $75K · 2022: $133K · 2023: $175K · 2024: $190K · 2025: $283K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $512K · Travel and Lodging: $73K · Consulting Fee: $47K · Food and Beverage: $16K · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $512,271.50 |
| Travel and Lodging | $72,514.19 |
| Consulting Fee | $47,205.50 |
| Food and Beverage | $16,048.02 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $415,461.20 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Alexion Pharmaceuticals, INC. | $140,463.61 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $117,980.95 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $85,776.57 | 2021-2025 | |
| Genentech USA, INC. | $49,362.05 | 2020-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $40,099.96 | 2021-2024 | Zeposia |
| Genzyme Corporation | $14,813.96 | 2019-2025 | |
| Celgene Corporation | $11,733.17 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $7,196.41 | 2019-2025 | |
| Ares Trading Sa | $7,050.00 | 2025 | |
| Horizon Therapeutics Plc | $4,041.66 | 2021-2022 | |
| Argenx US, INC. | $2,208.39 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Cycle Pharmaceuticals INC | $1,060.00 | 2023 | |
| Sk Life Science, INC. | $320.25 | 2022-2025 | Xcopri |
| Ucb, INC. | $263.46 | 2021-2025 | Zilbrysq, Rystiggo |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.